{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T15:06:44Z","timestamp":1792595204313,"version":"4.5.0"},"reference-count":94,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["cancertreatmentreviews.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.ctrv.2022.102443","type":"journal-article","created":{"date-parts":[[2022,7,31]],"date-time":"2022-07-31T02:28:06Z","timestamp":1659234486000},"page":"102443","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":160,"special_numbering":"C","title":["Treatment strategies for patients with diffuse large B-cell lymphoma"],"prefix":"10.1016","volume":"110","author":[{"given":"Stefano","family":"Poletto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mattia","family":"Novo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Paruzzo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pio Manlio Mirko","family":"Frascione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"Vitolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"9880","key":"10.1016\/j.ctrv.2022.102443_b0005","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1016\/S0140-6736(13)60313-X","article-title":"Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of dose intensification with 14-day versus 21-day cycles","volume":"381","author":"Cunningham","year":"2013","journal-title":"Lancet"},{"issue":"9806","key":"10.1016\/j.ctrv.2022.102443_b0010","doi-asserted-by":"crossref","first-page":"1858","DOI":"10.1016\/S0140-6736(11)61040-4","article-title":"Intensified chemotherapy with ACVBP plus rituximab versus standard CHOP plus rituximab for the treatment of diffuse large B-cell lymphoma (LNH03-2B): an open-label randomised phase 3 trial","volume":"378","author":"Recher","year":"2011","journal-title":"Lancet"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102443_b0015","doi-asserted-by":"crossref","first-page":"1076","DOI":"10.1016\/S1470-2045(17)30444-8","article-title":"Rituximab-dose-dense chemotherapy with or without high-dose chemotherapy plus autologous stem-cell transplantation in high-risk diffuse large B-cell lymphoma (DLCL04): final results of a multicentre, open-label, randomised, controlled, phase 3 study","volume":"18","author":"Chiappella","year":"2017","journal-title":"Lancet Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2022.102443_b0020","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1056\/NEJMoa1301077","article-title":"Autologous transplantation as consolidation for aggressive non-Hodgkin's lymphoma","volume":"369","author":"Stiff","year":"2013","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102443_b0025","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1016\/S1470-2045(12)70481-3","article-title":"Conventional chemotherapy (CHOEP-14) with rituximab or high-dose chemotherapy (MegaCHOEP) with rituximab for young, high-risk patients with aggressive B-cell lymphoma: an open-label, randomised, phase 3 trial (DSHNHL 2002\u20131)","volume":"13","author":"Schmitz","year":"2012","journal-title":"Lancet Oncol"},{"issue":"17","key":"10.1016\/j.ctrv.2022.102443_b0030","doi-asserted-by":"crossref","first-page":"2307","DOI":"10.1182\/blood.2020008750","article-title":"Obinutuzumab vs rituximab for advanced DLBCL: a PET-guided and randomized phase 3 study by LYSA","volume":"137","author":"Le Gouill","year":"2021","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.ctrv.2022.102443_b0035","doi-asserted-by":"crossref","first-page":"1790","DOI":"10.1200\/JCO.18.01994","article-title":"Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance\/CALGB 50303","volume":"37","author":"Bartlett","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102443_b0040","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1038\/s41375-018-0320-9","article-title":"Dose-adjusted EPOCH plus rituximab improves the clinical outcome of young patients affected by double expressor diffuse large B-cell lymphoma","volume":"33","author":"Dodero","year":"2019","journal-title":"Leukemia"},{"issue":"31","key":"10.1016\/j.ctrv.2022.102443_b0045","doi-asserted-by":"crossref","first-page":"3529","DOI":"10.1200\/JCO.2017.73.3402","article-title":"Obinutuzumab or rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in previously untreated diffuse large B-cell lymphoma","volume":"35","author":"Vitolo","year":"2017","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102443_b0050","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1200\/JCO.20.01375","article-title":"Addition of lenalidomide to R-CHOP improves outcomes in newly diagnosed diffuse large B-cell lymphoma in a randomized phase II US intergroup study ECOG-ACRIN E1412","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102443_b0055","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.20.01366","article-title":"ROBUST: a Phase III study of lenalidomide plus R-CHOP versus placebo plus R-CHOP in previously untreated patients with ABC-type diffuse large B-cell lymphoma","volume":"39","author":"Nowakowski","year":"2021","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.ctrv.2022.102443_b0060","doi-asserted-by":"crossref","first-page":"3538","DOI":"10.1200\/JCO.2017.73.2784","article-title":"Randomized phase II study of R-CHOP with or without bortezomib in previously untreated patients with non-germinal center B-cell-like diffuse large B-cell lymphoma","volume":"35","author":"Leonard","year":"2017","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102443_b0065","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(18)30935-5","article-title":"Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial","volume":"20","author":"Davies","year":"2019","journal-title":"Lancet Oncol"},{"issue":"15","key":"10.1016\/j.ctrv.2022.102443_b0070","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1200\/JCO.18.02403","article-title":"Randomized Phase III trial of ibrutinib and rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone in non-germinal Center B-cell diffuse large B-cell lymphoma","volume":"37","author":"Younes","year":"2019","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102443_b0075","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab vedotin in previously untreated diffuse large B-cell lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102443_b0080","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1182\/blood.2020006578","article-title":"A phase 2 study of venetoclax plus R-CHOP as first-line treatment for patients with diffuse large B-cell lymphoma","volume":"137","author":"Morschhauser","year":"2021","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102443_b0085","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3324\/haematol.2015.125344","article-title":"Rituximab maintenance for patients with aggressive B-cell lymphoma in first remission: results of the randomized NHL13 trial","volume":"100","author":"Jaeger","year":"2015","journal-title":"Haematologica"},{"issue":"31","key":"10.1016\/j.ctrv.2022.102443_b0090","doi-asserted-by":"crossref","first-page":"3490","DOI":"10.1200\/JCO.2013.53.9593","article-title":"Randomized comparison of gemcitabine, dexamethasone, and cisplatin versus dexamethasone, cytarabine, and cisplatin chemotherapy before autologous stem-cell transplantation for relapsed and refractory aggressive lymphomas: NCIC-CTG LY.12","volume":"32","author":"Crump","year":"2014","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102443_b0095","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1093\/annonc\/mdx764","article-title":"Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: final results from the PILLAR-2 randomized phase III trial","volume":"29","author":"Witzig","year":"2018","journal-title":"Ann Oncol"},{"issue":"22","key":"10.1016\/j.ctrv.2022.102443_b0100","doi-asserted-by":"crossref","first-page":"2473","DOI":"10.1200\/JCO.2017.72.6984","article-title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone","volume":"35","author":"Thieblemont","year":"2017","journal-title":"J Clin Oncol"},{"issue":"30","key":"10.1016\/j.ctrv.2022.102443_b0105","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1200\/JCO.2007.15.3429","article-title":"Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma","volume":"26","author":"Wiernik","year":"2008","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102443_b0110","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1200\/JCO.2014.55.5714","article-title":"Lenalidomide combined with R-CHOP overcomes negative prognostic impact of non-germinal center B-cell phenotype in newly diagnosed diffuse large B-Cell lymphoma: a phase II study","volume":"33","author":"Nowakowski","year":"2015","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102443_b0115","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1016\/S1470-2045(14)70191-3","article-title":"Lenalidomide plus R-CHOP21 in elderly patients with untreated diffuse large B-cell lymphoma: results of the REAL07 open-label, multicentre, phase 2 trial","volume":"15","author":"Vitolo","year":"2014","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.ctrv.2022.102443_b0120","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1038\/nm.3884","article-title":"Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma","volume":"21","author":"Wilson","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2022.102443_b0125","unstructured":"A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312). ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04529772 (accessed Feb 6, 2022)."},{"issue":"21","key":"10.1016\/j.ctrv.2022.102443_b0130","doi-asserted-by":"crossref","first-page":"2484","DOI":"10.1200\/JCO.2015.65.7171","article-title":"Randomized, double-blind, phase III trial of enzastaurin versus placebo in patients achieving remission after first-line therapy for high-risk diffuse large B-cell lymphoma","volume":"34","author":"Crump","year":"2016","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.ctrv.2022.102443_b0135","doi-asserted-by":"crossref","first-page":"1540","DOI":"10.1056\/NEJM199512073332305","article-title":"Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin's lymphoma","volume":"333","author":"Philip","year":"1995","journal-title":"N Engl J Med"},{"issue":"27","key":"10.1016\/j.ctrv.2022.102443_b0140","doi-asserted-by":"crossref","first-page":"4184","DOI":"10.1200\/JCO.2010.28.1618","article-title":"Salvage regimens with autologous transplantation for relapsed large B-cell lymphoma in the rituximab era","volume":"28","author":"Gisselbrecht","year":"2010","journal-title":"J Clin Oncol"},{"issue":"31","key":"10.1016\/j.ctrv.2022.102443_b0145","doi-asserted-by":"crossref","first-page":"4079","DOI":"10.1200\/JCO.2011.35.4423","article-title":"The germinal center\/activated B-cell subclassification has a prognostic impact for response to salvage therapy in relapsed\/refractory diffuse large B-cell lymphoma: a bio-CORAL study","volume":"29","author":"Thieblemont","year":"2011","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102443_b0150","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/sj.bmt.1700913","article-title":"BEAM chemotherapy followed by autologous stem cell support in lymphoma patients: analysis of efficacy, toxicity and prognostic factors","volume":"20","author":"Caballero","year":"1997","journal-title":"Bone Marrow Transplant"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102443_b0155","doi-asserted-by":"crossref","first-page":"2279","DOI":"10.1002\/cncr.32752","article-title":"Outcomes of rituximab-BEAM versus BEAM conditioning regimen in patients with diffuse large B cell lymphoma undergoing autologous transplantation","volume":"126","author":"Jagadeesh","year":"2020","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.ctrv.2022.102443_b0160","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102443_b0165","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S1470-2045(18)30864-7","article-title":"Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1\u20132 trial","volume":"20","author":"Locke","year":"2019","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102443_b0170","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"issue":"10254","key":"10.1016\/j.ctrv.2022.102443_b0175","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"issue":"27","key":"10.1016\/j.ctrv.2022.102443_b0180","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1200\/JCO.19.02104","article-title":"Standard-of-care axicabtagene ciloleucel for relapsed or refractory large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"38","author":"Nastoupil","year":"2020","journal-title":"J Clin Oncol"},{"issue":"21","key":"10.1016\/j.ctrv.2022.102443_b0185","doi-asserted-by":"crossref","first-page":"5414","DOI":"10.1182\/bloodadvances.2020003092","article-title":"Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma","volume":"4","author":"Pasquini","year":"2020","journal-title":"Blood Adv"},{"issue":"27","key":"10.1016\/j.ctrv.2022.102443_b0190","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102443_b0195","doi-asserted-by":"crossref","DOI":"10.1182\/blood.2021015209","article-title":"GLA\/DRST real-world outcome analysis of CAR-T cell therapies for large B-cell lymphoma in Germany","author":"Bethge","year":"2022","journal-title":"Blood"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102443_b0200","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line tisagenlecleucel or standard care in aggressive B-Cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"issue":"10343","key":"10.1016\/j.ctrv.2022.102443_b0205","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102443_b0210","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.ctrv.2022.102443_b0215","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41591-022-01731-4","article-title":"Axicabtagene ciloleucel as first-line therapy in high-risk large B-cell lymphoma: the phase 2 ZUMA-12 trial","volume":"28","author":"Neelapu","year":"2022","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102443_b0220","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1038\/s41551-021-00842-6","article-title":"Rapid manufacturing of non-activated potent CAR T cells","volume":"6","author":"Ghassemi","year":"2022","journal-title":"Nat Biomed Eng"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102443_b0225","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","article-title":"Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia","volume":"24","author":"Fraietta","year":"2018","journal-title":"Nat Med"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2022.102443_b0230","article-title":"Long-Term Follow-up ZUMA-1: A Pivotal Trial of Axicabtagene Ciloleucel (Axi-Cel; KTE-C19) in Patients with Refractory Aggressive Non-Hodgkin Lymphoma (NHL)","volume":"130","author":"Neelapu","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102443_b0235","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/s13045-018-0629-x","article-title":"T cell senescence and CAR-T cell exhaustion in hematological malignancies","volume":"11","author":"Kasakovski","year":"2018","journal-title":"J Hematol Oncol"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102443_b0240","doi-asserted-by":"crossref","first-page":"3383","DOI":"10.1038\/s41375-021-01281-7","article-title":"Determinants of CD19-positive vs CD19-negative relapse after tisagenlecleucel for B-cell acute lymphoblastic leukemia","volume":"35","author":"Dourthe","year":"2021","journal-title":"Leukemia"},{"issue":"Supplement_1","key":"10.1016\/j.ctrv.2022.102443_b0245","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-126218","article-title":"CD19-loss with preservation of other B cell lineage features in patients with large B cell lymphoma who relapsed post-axi-cel","volume":"134","author":"Neelapu","year":"2019","journal-title":"Blood"},{"issue":"17","key":"10.1016\/j.ctrv.2022.102443_b0250","doi-asserted-by":"crossref","first-page":"1980","DOI":"10.1182\/blood.2020005123","article-title":"Transdifferentiation of lymphoma into sarcoma associated with profound reprogramming of the epigenome","volume":"136","author":"Zhang","year":"2020","journal-title":"Blood"},{"issue":"10","key":"10.1016\/j.ctrv.2022.102443_b0255","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin's lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol"},{"issue":"20","key":"10.1016\/j.ctrv.2022.102443_b0260","doi-asserted-by":"crossref","first-page":"4256","DOI":"10.1182\/blood-2012-06-436725","article-title":"Conditioning regimens for allotransplants for diffuse large B-cell lymphoma: myeloablative or reduced intensity?","volume":"120","author":"Bacher","year":"2012","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ctrv.2022.102443_b0265","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1182\/bloodadvances.2018027748","article-title":"PTCy-based haploidentical vs matched related or unrelated donor reduced-intensity conditioning transplant for DLBCL","volume":"3","author":"Dreger","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102443_b0270","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1200\/JCO.20.01447","article-title":"Is there still a role for allogeneic transplantation in the management of lymphoma?","volume":"39","author":"Shah","year":"2021","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102443_b0275","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10061173","article-title":"Post-transplant cyclophosphamide and tacrolimus-mycophenolate mofetil combination governs GVHD and immunosuppression need, reducing late toxicities in allogeneic peripheral blood hematopoietic cell transplantation from HLA-matched donors","volume":"10","author":"Carnevale-Schianca","year":"2021","journal-title":"J Clin Med"},{"issue":"7","key":"10.1016\/j.ctrv.2022.102443_b0280","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102443_b0285","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1200\/JCO.21.00931","article-title":"Single-agent mosunetuzumab shows durable complete responses in patients with relapsed or refractory B-cell lymphomas: phase I dose-escalation study","volume":"40","author":"Budde","year":"2022","journal-title":"J Clin Oncol"},{"issue":"18","key":"10.1016\/j.ctrv.2022.102443_b0290","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1200\/JCO.20.03175","article-title":"Glofitamab, a novel, bivalent CD20-targeting T-cell-engaging bispecific antibody, induces durable complete remissions in relapsed or refractory B-cell lymphoma: a phase I trial","volume":"39","author":"Hutchings","year":"2021","journal-title":"J Clin Oncol"},{"issue":"10306","key":"10.1016\/j.ctrv.2022.102443_b0295","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1016\/S0140-6736(21)00889-8","article-title":"Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1\/2 study","volume":"398","author":"Hutchings","year":"2021","journal-title":"Lancet"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2022.102443_b0300","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1182\/blood-2020-136659","article-title":"Odronextamab (REGN1979), a human CD20 x CD3 Bispecific antibody, induces durable, complete responses in patients with highly refractory B-cell non-hodgkin lymphoma, including patients refractory to CAR T therapy","volume":"136","author":"Bannerji","year":"2020","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.ctrv.2022.102443_b0305","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2019-128564","article-title":"Preliminary safety and anti-tumor activity of XmAb13676, an anti-CD20 x anti-CD3 bispecific antibody, in patients with relapsed\/refractory non-hodgkin's lymphoma and chronic lymphocytic leukemia","volume":"134","author":"Patel","year":"2019","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102443_b0310","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2021005794","article-title":"Polatuzumab vedotin plus bendamustine and rituximab in relapsed\/refractory DLBCL: survival update and new extension cohort data","volume":"6","author":"Sehn","year":"2022","journal-title":"Blood Adv"},{"issue":"19","key":"10.1016\/j.ctrv.2022.102443_b0315","doi-asserted-by":"crossref","first-page":"2634","DOI":"10.1182\/blood.2020007512","article-title":"Final results of a phase 1 study of loncastuximab tesirine in relapsed\/refractory B-cell non-Hodgkin lymphoma","volume":"137","author":"Hamadani","year":"2021","journal-title":"Blood"},{"issue":"6","key":"10.1016\/j.ctrv.2022.102443_b0320","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): a multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.ctrv.2022.102443_b0325","doi-asserted-by":"crossref","first-page":"8049","DOI":"10.1158\/0008-5472.CAN-08-2268","article-title":"Potent in vitro and in vivo activity of an Fc-engineered anti-CD19 monoclonal antibody against lymphoma and leukemia","volume":"68","author":"Horton","year":"2008","journal-title":"Can Res"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102443_b0330","doi-asserted-by":"crossref","first-page":"1266","DOI":"10.1093\/annonc\/mdy056","article-title":"Phase IIa study of the CD19 antibody MOR208 in patients with relapsed or refractory B-cell non-Hodgkin's lymphoma","volume":"29","author":"Jurczak","year":"2018","journal-title":"Ann Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2022.102443_b0335","doi-asserted-by":"crossref","DOI":"10.1182\/blood-2021-148302","article-title":"Tafasitamab plus lenalidomide versus Pola-BR, R2, and CAR T: comparing outcomes from RE-MIND2, an observational, retrospective cohort study in relapsed\/refractory diffuse large B-cell lymphoma","volume":"138","author":"Nowakowski","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2022.102443_b0340","first-page":"153","article-title":"Antibody therapies for large B-cell lymphoma","volume":"15","author":"Novo","year":"2021","journal-title":"Biologics"},{"issue":"19","key":"10.1016\/j.ctrv.2022.102443_b0345","doi-asserted-by":"crossref","first-page":"4785","DOI":"10.1158\/1078-0432.CCR-18-0455","article-title":"CD20-TCB with obinutuzumab pretreatment as next-generation treatment of hematologic malignancies","volume":"24","author":"Bacac","year":"2018","journal-title":"Clin Can Res"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2022.102443_b0350","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7500","article-title":"Glofitamab in patients with relapsed\/refractory (R\/R) diffuse large B-cell lymphoma (DLBCL) and \u2265 2 prior therapies: pivotal phase II expansion results","volume":"40","author":"Dickinson","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102443_b0355","unstructured":"Thieblemont C et al. Primary results of subcutaneous epcoritamab dose expansion in patients with relapsed or refractory large B-cell lymphoma: a phase 2 study. Presented at: 2022 EHA Annual Meeting; June 9-17, 2022; Vienna, Austria. Abstract LB2364. https:\/\/bit.ly\/3xq326p."},{"issue":"6","key":"10.1016\/j.ctrv.2022.102443_b0360","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1016\/S1470-2045(15)70128-2","article-title":"Safety and activity of the anti-CD79B antibody-drug conjugate polatuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study","volume":"16","author":"Palanca-Wessels","year":"2015","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.ctrv.2022.102443_b0365","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1200\/JCO.19.00172","article-title":"Polatuzumab vedotin in relapsed or refractory diffuse large B-cell lymphoma","volume":"38","author":"Sehn","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ctrv.2022.102443_b0370","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1080\/10428194.2020.1824069","article-title":"Outcome of relapsed\/refractory diffuse large B-cell lymphoma patients treated with polatuzumab vedotin-based therapy: real-life experience","volume":"62","author":"Segman","year":"2021","journal-title":"Leuk Lymphoma"},{"issue":"13","key":"10.1016\/j.ctrv.2022.102443_b0375","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/bloodadvances.2020004155","article-title":"Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas","volume":"5","author":"Liebers","year":"2021","journal-title":"Blood Adv"},{"key":"10.1016\/j.ctrv.2022.102443_b0380","doi-asserted-by":"crossref","unstructured":"Haioun C et al. POLARGO: Randomized Phase III study of polatuzumab vedotin plus rituximab, gemcitabine, and oxaliplatin (R-GemOx) in relapsed\/refractory diffuse large B-cell lymphoma (R\/R DLBCL). J Clin Oncol, 2020;38(15_suppl): p. TPS8070-TPS8070.","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS8070"},{"key":"10.1016\/j.ctrv.2022.102443_b0385","article-title":"Carboplatin, and Etoposide (PolaR-ICE) as Initial Salvage Therapy for the Treatment of Relapsed\/Refractory Diffuse Large B-Cell Lymphoma","author":"Vedotin","year":"2021","journal-title":"ClinicalTrialsgov"},{"key":"10.1016\/j.ctrv.2022.102443_b0390","unstructured":"A Study to Evaluate the Safety and Anti-cancer Activity of Loncastuximab Tesirine in Combination With Other Anti-cancer Agents in Participants With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma (LOTIS 7). ClinicalTrials.gov. https:\/\/www.clinicaltrials.gov\/ct2\/show\/NCT04970901 (accessed Jan 30, 2022)."},{"key":"10.1016\/j.ctrv.2022.102443_b0395","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1182\/blood-2021-147765","article-title":"Planned interim analysis of a phase 2 study of loncastuximab tesirine plus ibrutinib in patients with advanced diffuse large B-cell lymphoma (LOTIS-3)","volume":"138","author":"Carlo-Stella","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2022.102443_b0400","doi-asserted-by":"crossref","unstructured":"Belada D. et al. First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL. Journal of Clinical Oncology, 2021. 39(15_suppl): p. 7540-7540.","DOI":"10.1200\/JCO.2021.39.15_suppl.7540"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2022.102443_b0405","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.TPS7590","article-title":"frontMIND: A phase III, randomized, double-blind study of tafasitamab + lenalidomide + R-CHOP versus R-CHOP alone for newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma","volume":"40","author":"Vitolo","year":"2022","journal-title":"J Clin Oncol"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2022.102443_b0410","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1182\/blood-2020-136295","article-title":"Mosunetuzumab, a novel CD20\/CD3 bispecific antibody, in combination with CHOP confers high response rates in patients with diffuse large B-cell lymphoma","volume":"136","author":"Phillips","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2022.102443_b0415","unstructured":"Trial of Mosunetuzumab (BTCT4465A) as Consolidation Therapy in Participants With Diffuse Large B-Cell Lymphoma Following First-Line Immunochemotherapy and as Monotherapy or in Combination With Polatuzumab Vedotin in Elderly\/Unfit Participants With Previously Untreated Diffuse Large B-Cell Lymphoma. ClinicalTrials.gov. https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03677154 (accessed Feb 13, 2021)."},{"key":"10.1016\/j.ctrv.2022.102443_b0420","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1182\/blood-2020-136255","article-title":"Single-agent mosunetuzumab is a promising safe and efficacious chemotherapy-free regimen for elderly\/unfit patients with previously untreated diffuse large B-cell lymphoma","volume":"136","author":"Olszewski","year":"2020","journal-title":"Blood"},{"issue":"Supplement 1","key":"10.1016\/j.ctrv.2022.102443_b0425","volume":"138","author":"Ghosh","year":"2021","journal-title":"Blood"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2022.102443_b0430","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7523","article-title":"First-line treatment (Tx) with subcutaneous (SC) epcoritamab (epco) + R-CHOP in patients (pts) with high-risk diffuse large B-cell lymphoma (DLBCL): Phase 1\/2 data update","volume":"40","author":"Falchi","year":"2022","journal-title":"J Clin Oncol"},{"issue":"16_suppl","key":"10.1016\/j.ctrv.2022.102443_b0435","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2022.40.16_suppl.7527","volume":"40","author":"Brody","year":"2022","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2022.102443_b0440","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1182\/blood-2021-148009","article-title":"Primary analysis of ZUMA-12: a phase 2 Study of Axicabtagene Ciloleucel (Axi-Cel) as first-line therapy in patients with high-risk large B-cell lymphoma (LBCL)","volume":"138","author":"Neelapu","year":"2021","journal-title":"Blood"},{"issue":"6769","key":"10.1016\/j.ctrv.2022.102443_b0445","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/35000501","article-title":"Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling","volume":"403","author":"Alizadeh","year":"2000","journal-title":"Nature"},{"issue":"20","key":"10.1016\/j.ctrv.2022.102443_b0450","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1182\/blood-2016-01-643569","article-title":"The 2016 revision of the World Health Organization classification of lymphoid neoplasms","volume":"127","author":"Swerdlow","year":"2016","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.ctrv.2022.102443_b0455","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","article-title":"Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes","volume":"24","author":"Chapuy","year":"2018","journal-title":"Nat Med"},{"issue":"15","key":"10.1016\/j.ctrv.2022.102443_b0460","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMoa1801445","article-title":"Genetics and pathogenesis of diffuse large B-cell lymphoma","volume":"378","author":"Schmitz","year":"2018","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ctrv.2022.102443_b0465","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1016\/j.ccell.2021.10.006","article-title":"Effect of ibrutinib with R-CHOP chemotherapy in genetic subtypes of DLBCL","volume":"39","author":"Wilson","year":"2021","journal-title":"Cancer Cell"},{"issue":"S2","key":"10.1016\/j.ctrv.2022.102443_b0470","doi-asserted-by":"crossref","DOI":"10.1002\/hon.26_2879","article-title":"Genetic subtype guided rituximab-based immunochemotherapy improves outcome in newly diagnosed diffuse large B-cell lymphoma: first report of a randomized phase 2 study","volume":"39","author":"Zhang","year":"2021","journal-title":"Hematol Oncol"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001128?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737222001128?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,5]],"date-time":"2025-10-05T09:26:50Z","timestamp":1759656410000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737222001128"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":94,"alternative-id":["S0305737222001128"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102443","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treatment strategies for patients with diffuse large B-cell lymphoma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2022.102443","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"102443"}}